RNAi technology

Roche Teams up with Alnylam for Antihypertensive Drug

Swiss pharmaceutical company Roche will collaborate with Cambridge, Massachusetts-based US biotech Alnylam Pharmaceuticals to further develop its drug zilebesiran for the treatment of hypertension. The therapeutic, which is in Phase 2 clinical trials, uses the cellular mechanism RNA interference (RNAi) for targeted gene silencing.

News

Syngenta Pays Big Premium for Seed Firm Devgen

News

Seed Firm Devgen Signs Syngenta Pesticide Deal

Top-Feature

CHEManager International c/o Wiley-VCH GmbH

Upcoming Virtual Events

SCIEX

Capillary Electrophoresis in Biotherapeutic Development: Platform Methods, Fragment Workflows, and ADC Characterization

Agilent Technologies Inc.

Comprehensive Insights into Antibody–Drug Conjugates (ADC) for Precision Cancer Therapy

Citrine

Operationalizing AI in Polymer Development: How Syensqo Is Scaling Impact with the Citrine Platform

Aenova Holding GmbH

Mastering Modified Release: The Pellet-Based Approach

Global Impact Coalition (GIC)

Siemens Joins the Global Impact Coalition

Evonik Industries AG

Safer, Scalable Pharmaceutical Manufacturing with Flow Chemistry

Article

Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.